PLYMOUTH MEETING, Pa., April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results